自给注射的肉毒素注射导致系统性肉毒素的罕见伪装
Kai Wen Elvina Tay1, Alvin Ong1, Wei Ling Tay2
1Post-Acute and Continuing Care, Jurong Community Hospital, Singapore, SGP.
Cureus
|August 20, 2024
概括
一名患者在接受了土毒素A (BoNT-A) 的化品注射后出现了全身性肉毒症. 这一案例突出了自我服用神经毒素的罕见但严重的并发症.
科学领域:
- 医学案例报告 病例报告
- 毒理学 毒理学 毒理学
- 神经学 神经学
背景情况:
- 系统性肉毒是一种罕见的神经麻性疾病.
- 在化品中使用的甲基毒素A (BoNT-A) 正在增加.
- 自治BoNT-A具有潜在的风险.
研究的目的:
- 报告一个系统性肉毒主义病例.
- 为了突出自我管理的化品毒素的风险.
- 提高医疗保健提供者的意识.
主要方法:
- 一个患有神经症状的患者的案例研究.
- 检查患者病史,包括最近的美容手术.
- 肉毒主义的临床评估和诊断.
主要成果:
- 患者出现呼吸困难,虚弱,消化不良和步态障碍.
- 症状暂时与自己注射100个单位BoNT-A有关.
- 系统性肉毒主义的诊断得到证实.
结论:
- 用于化品目的自给自取的甲胺毒素A可以导致全身性肉毒.
- 当患者出现神经症状时,医生应询问有关化品的程序.
- 提高公众对自我使用神经毒素的风险的认识至关重要.
更多相关视频
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
662
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
662
Skeletal Muscle Relaxants: Therapeutic Uses
477
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
477
Depolarizing Blockers: Pharmocokinetics
316
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
316
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
402
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
402
Myasthenia Gravis: Diagnostic Tests
714
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
714


